IN2015DN03909A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN03909A IN2015DN03909A IN3909DEN2015A IN2015DN03909A IN 2015DN03909 A IN2015DN03909 A IN 2015DN03909A IN 3909DEN2015 A IN3909DEN2015 A IN 3909DEN2015A IN 2015DN03909 A IN2015DN03909 A IN 2015DN03909A
- Authority
- IN
- India
- Prior art keywords
- chloro
- methyl
- ethyl
- amino
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- GWZMWAZUCSGVLQ-UHFFFAOYSA-N 3-chloro-1-methylpyrazole Chemical compound CN1C=CC(Cl)=N1 GWZMWAZUCSGVLQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004212 difluorophenyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 abstract 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716780P | 2012-10-22 | 2012-10-22 | |
| PCT/US2013/065827 WO2014066202A1 (en) | 2012-10-22 | 2013-10-21 | Combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03909A true IN2015DN03909A (enExample) | 2015-10-02 |
Family
ID=50545138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3909DEN2015 IN2015DN03909A (enExample) | 2012-10-22 | 2013-10-21 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150272952A1 (enExample) |
| EP (1) | EP2908815A4 (enExample) |
| JP (1) | JP2015534986A (enExample) |
| KR (1) | KR20150074097A (enExample) |
| CN (1) | CN104902899A (enExample) |
| AU (1) | AU2013334943A1 (enExample) |
| BR (1) | BR112015008924A2 (enExample) |
| CA (1) | CA2889051A1 (enExample) |
| IN (1) | IN2015DN03909A (enExample) |
| MX (1) | MX2015005113A (enExample) |
| RU (1) | RU2015119245A (enExample) |
| WO (1) | WO2014066202A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| PT2485593E (pt) * | 2009-10-08 | 2015-04-28 | Glaxosmithkline Llc | Associação |
| WO2011060380A1 (en) * | 2009-11-14 | 2011-05-19 | The Regents Of The University Of California | Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer |
| JP2013526578A (ja) * | 2010-05-21 | 2013-06-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
-
2013
- 2013-10-21 CN CN201380067522.7A patent/CN104902899A/zh active Pending
- 2013-10-21 JP JP2015538098A patent/JP2015534986A/ja active Pending
- 2013-10-21 WO PCT/US2013/065827 patent/WO2014066202A1/en not_active Ceased
- 2013-10-21 US US14/437,297 patent/US20150272952A1/en not_active Abandoned
- 2013-10-21 CA CA2889051A patent/CA2889051A1/en not_active Abandoned
- 2013-10-21 RU RU2015119245A patent/RU2015119245A/ru not_active Application Discontinuation
- 2013-10-21 IN IN3909DEN2015 patent/IN2015DN03909A/en unknown
- 2013-10-21 AU AU2013334943A patent/AU2013334943A1/en not_active Abandoned
- 2013-10-21 EP EP13848997.6A patent/EP2908815A4/en not_active Withdrawn
- 2013-10-21 KR KR1020157013079A patent/KR20150074097A/ko not_active Withdrawn
- 2013-10-21 MX MX2015005113A patent/MX2015005113A/es unknown
- 2013-10-21 BR BR112015008924A patent/BR112015008924A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015008924A2 (pt) | 2017-07-04 |
| CN104902899A (zh) | 2015-09-09 |
| RU2015119245A (ru) | 2016-12-10 |
| US20150272952A1 (en) | 2015-10-01 |
| MX2015005113A (es) | 2015-10-29 |
| KR20150074097A (ko) | 2015-07-01 |
| EP2908815A4 (en) | 2016-06-22 |
| EP2908815A1 (en) | 2015-08-26 |
| WO2014066202A1 (en) | 2014-05-01 |
| AU2013334943A1 (en) | 2015-05-14 |
| CA2889051A1 (en) | 2014-05-01 |
| JP2015534986A (ja) | 2015-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| PH12015501965B1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| MY191357A (en) | Sustained-release dosage forms of ruxolitinib | |
| PH12016502355B1 (en) | Pharmaceutical composition | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| PH12013500924A1 (en) | Compositions and methods for treating myelofibrosis | |
| MX356704B (es) | Combinación. | |
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| MX2015011614A (es) | Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX359770B (es) | Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r. | |
| MX2016004934A (es) | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| EA201491427A1 (ru) | Замещенные фенилимидазопиразолы и их применение | |
| AU2012280776B2 (en) | Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases | |
| IN2014DN02060A (enExample) | ||
| TW201129361A (en) | Methods for treating pain | |
| MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. | |
| IN2015DN03909A (enExample) | ||
| CA3069989C (en) | METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG | |
| PH12014502400A1 (en) | Treatment method for steroid responsive dermatoses |